• Coya Therapeutics released an investor presentation outlining its Treg-directed combination-therapy strategy for neurodegenerative diseases.
• Lead program COYA 302 targets ALS with Phase 2 ALSTARS enrollment expected to finish in H2 2026; topline data expected in Q1 2027.
• Collaboration with Dr. Reddy’s includes up to about $700 million in milestones, mid-teen royalties, and a $10 million equity investment.
• Cash totaled $43.2 million as of June 30, 2026; runway projected into H2 2027.
• Shares outstanding were about 23,500,000 as of Aug. 11, 2026; Greenlight Capital held 9.9%, Dr. Reddy’s held 9.7%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Coya Therapeutics Inc. published the original content used to generate this news brief on September 01, 2026, and is solely responsible for the information contained therein.